Literature DB >> 29956427

Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.

E D'Amico1, F Patti1, A Zanghì1, C G Chisari1, S Lo Fermo1, M Zappia1.   

Abstract

BACKGROUND AND
PURPOSE: Late-onset multiple sclerosis (MS) has a prevalence of about 10-20% in natural history MS studies. Few data have been published about the long-term disease trajectory in the cohort of late-onset relapsing-remitting MS (LORRMS). The aim of this study was to identify the risk factors for reaching an Expanded Disability Status Scale (EDSS) score of 6.0 in LORRMS (onset at >40 years of age) and young-onset relapsing-remitting MS (YORRMS) (onset between 18 and 40 years of age).
METHODS: Clinical and radiological [magnetic resonance imaging (MRI) of the brain] follow-up data were collected. Disability was assessed by EDSS score. A Cox proportional hazards model was used to evaluate the demographic and clinical predictors of reaching an EDSS score of 6.0 in the two cohorts.
RESULTS: A total of 671 patients with relapsing-remitting MS were enrolled, 143 (21.3%) with LORRMS and 528 (78.7%) with YORRMS. In LORRMS, age at onset was 47.8 ± 5.3 (mean ± SD) years and duration of follow-up was 120.7 ± 52.7 months. In YORRMS, age at onset was 27 ± 2.7 years and duration of follow-up was 149.9 ± 92.7 months. The survival curve analyses showed a higher probability of reaching an EDSS score of 6.0 for LORRMS in a shorter time (months) than for YORRMS (94.2 vs. 103.2 months; log-rank 8.8; P < 0.05). On MRI, YORRMS showed more brain inflammatory features than LORRMS. In the multivariate Cox model, age at onset [Exp(B) value, 6.5; 95% confidence interval, 1.9-22.6; P < 0.001] and male gender [Exp(B) value, 1.7; 95% confidence interval, 1.0-2.8; P < 0.05] were the strongest predictors of reaching an EDSS score of 6.0.
CONCLUSIONS: The male population with LORRMS reached severe disability faster than those with YORRMS, even when YORRMS showed more brain inflammatory features on MRI.
© 2018 EAN.

Entities:  

Keywords:  disease course; late onset; multiple sclerosis; relapsing-remitting; young onset

Mesh:

Year:  2018        PMID: 29956427     DOI: 10.1111/ene.13745

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  15 in total

1.  Late-onset MS is associated with an increased rate of reaching disability milestones.

Authors:  Mads Albrecht Andersen; Mathias Due Buron; Melinda Magyari
Journal:  J Neurol       Date:  2021-03-07       Impact factor: 4.849

2.  Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis.

Authors:  Mehdi Rezaee; Mohammad Hossein Morowvat; Maryam Poursadeghfard; Armin Radgoudarzi; Khosro Keshavarz
Journal:  BMC Health Serv Res       Date:  2022-01-28       Impact factor: 2.655

3.  Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis.

Authors:  Efrat Neter; Lea Glass-Marmor; Anat Wolkowitz; Idit Lavi; Ariel Miller
Journal:  BMC Neurol       Date:  2021-03-25       Impact factor: 2.474

Review 4.  FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models.

Authors:  Ranjithkumar Rajendran; Gregor Böttiger; Christine Stadelmann; Srikanth Karnati; Martin Berghoff
Journal:  Cells       Date:  2021-04-13       Impact factor: 6.600

5.  Exploring polypharmacy phenomenon in newly diagnosed relapsing-remitting multiple sclerosis: a cohort ambispective single-centre study.

Authors:  Aurora Zanghì; Emanuele D'Amico; Salvatore Lo Fermo; Francesco Patti
Journal:  Ther Adv Chronic Dis       Date:  2021-02-27       Impact factor: 5.091

Review 6.  Vitamin D and Depressive Symptoms in Adults with Multiple Sclerosis: A Scoping Review.

Authors:  Carmen Concerto; Alessandro Rodolico; Alessia Ciancio; Christian Messina; Antimo Natale; Ludovico Mineo; Fortunato Battaglia; Eugenio Aguglia
Journal:  Int J Environ Res Public Health       Date:  2021-12-25       Impact factor: 3.390

7.  Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.

Authors:  Huah Shin Ng; Jonas Graf; Feng Zhu; Elaine Kingwell; Orhan Aktas; Philipp Albrecht; Hans-Peter Hartung; Sven G Meuth; Charity Evans; John D Fisk; Ruth Ann Marrie; Yinshan Zhao; Helen Tremlett
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

8.  First-line therapies in late-onset multiple sclerosis: An Italian registry study.

Authors:  Aurora Zanghì; Carlo Avolio; Maria Pia Amato; Massimo Filippi; Maria Trojano; Francesco Patti; Emanuele D'Amico
Journal:  Eur J Neurol       Date:  2021-07-30       Impact factor: 6.288

Review 9.  Mechanisms of sex hormones in autoimmunity: focus on EAE.

Authors:  Ninaad Lasrado; Ting Jia; Chandirasegaran Massilamany; Rodrigo Franco; Zsolt Illes; Jay Reddy
Journal:  Biol Sex Differ       Date:  2020-09-07       Impact factor: 5.027

10.  Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.

Authors:  Zhao Zhao; Yang Lv; Zhi-Chun Gu; Chun-Lai Ma; Ming-Kang Zhong
Journal:  Front Immunol       Date:  2021-12-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.